Chitosan-coated bovine serum albumin nanoparticles for topical tetrandrine delivery in glaucoma: in vitro and in vivo assessment

Glaucoma is one of the leading causes of blindness. Therapies available suffer from several drawbacks including low bioavailability, repeated administration and poor patient compliance with adverse effects thereafter. In this study, bovine serum albumin nanoparticles (BSA-NPs) coated with chitosan(C...

Full description

Saved in:
Bibliographic Details
Main Authors: Salma El-Sayed Radwan (Author), Riham M. El-Moslemany (Author), Radwa A. Mehanna (Author), Eman H. Thabet (Author), Elsayeda-Zeinab A. Abdelfattah (Author), Amal El-Kamel (Author)
Format: Book
Published: Taylor & Francis Group, 2022-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_1b94b153cd5a46e5ae9bde8acb5f8ce1
042 |a dc 
100 1 0 |a Salma El-Sayed Radwan  |e author 
700 1 0 |a Riham M. El-Moslemany  |e author 
700 1 0 |a Radwa A. Mehanna  |e author 
700 1 0 |a Eman H. Thabet  |e author 
700 1 0 |a Elsayeda-Zeinab A. Abdelfattah  |e author 
700 1 0 |a Amal El-Kamel  |e author 
245 0 0 |a Chitosan-coated bovine serum albumin nanoparticles for topical tetrandrine delivery in glaucoma: in vitro and in vivo assessment 
260 |b Taylor & Francis Group,   |c 2022-12-01T00:00:00Z. 
500 |a 10.1080/10717544.2022.2058648 
500 |a 1521-0464 
500 |a 1071-7544 
520 |a Glaucoma is one of the leading causes of blindness. Therapies available suffer from several drawbacks including low bioavailability, repeated administration and poor patient compliance with adverse effects thereafter. In this study, bovine serum albumin nanoparticles (BSA-NPs) coated with chitosan(CS) were developed for the topical delivery of tetrandrine (TET) for glaucoma management. Optimized nanoparticles were prepared by desolvation. pH, BSA, CS and cross-linking agent concentrations effects on BSA-NPs colloidal properties were investigated. CS-BSA-NPs with particle size 237.9 nm and zeta potential 24 mV was selected for further evaluation. EE% exceeded 95% with sustained release profile. In vitro mucoadhesion was evaluated based on changes in viscosity and zeta potential upon incubation with mucin. Ex vivo transcorneal permeation was significantly enhanced for CS coated formulation. In vitro cell culture studies on corneal stromal fibroblasts revealed NPs biocompatibility with enhanced cellular uptake and improved antioxidant and anti-proliferative properties for the CS-coated formulation. Moreover, BSA-NPs were nonirritant as shown by HET-CAM test. Also, bioavailability in rabbit aqueous humor showed 2-fold increase for CS-TET-BSA-NPs compared to TET with a sustained reduction in intraocular pressure in a rabbit glaucoma model. Overall, results suggest CS-BSA-NPs as a promising platform for topical ocular TET delivery in the management of glaucoma. 
546 |a EN 
690 |a Tetrandrine 
690 |a chitosan 
690 |a albumin nanoparticles 
690 |a glaucoma 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Drug Delivery, Vol 29, Iss 1, Pp 1150-1163 (2022) 
787 0 |n https://www.tandfonline.com/doi/10.1080/10717544.2022.2058648 
787 0 |n https://doaj.org/toc/1071-7544 
787 0 |n https://doaj.org/toc/1521-0464 
856 4 1 |u https://doaj.org/article/1b94b153cd5a46e5ae9bde8acb5f8ce1  |z Connect to this object online.